

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

<https://marketpublishers.com/r/C957821060CEN.html>

Date: September 2016

Pages: 142

Price: US\$ 5,650.00 (Single User License)

ID: C957821060CEN

Abstracts

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the cancer immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, end user, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the

largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

OBJECTIVES OF THE STUDY

To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region

To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market

To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)

To profile the key players and comprehensively analyze their market shares and core competencies

To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market

Target Audience for this Report:

Drug Manufacturers and Suppliers

Academic Research Institutes

Hospitals and Clinics

Research and Development (R&D) Companies

Business Research and Consulting Service Providers

Medical Research Laboratories

Academic Medical Centers and Universities

Scope of the Report:

In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:

Cancer Immunotherapy Market, by Type

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Cancer Immunotherapy Market, by Application

Lung Cancer

Breast Cancer

Head and Neck Cancer

Prostate Cancer

Colorectal Cancer

Melanoma

Others

Cancer Immunotherapy Market, by End User

Hospitals

Clinics & Others

Cancer Immunotherapy Market, by Region

North America

U.S.

Canada

Europe

Germany

France

Italy

U.K.

Spain

RoE

APAC

India

China

Japan

RoAPAC

Rest of the World (RoW)

South America, Central America, and the Caribbean

Oceania

Africa

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKETS COVERED
 - 1.3.1 PERIODIZATION
- 1.4 CURRENCY
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 KEY DATA FROM SECONDARY SOURCES
 - 2.1.2 KEY DATA FROM PRIMARY SOURCES
- 2.2 MARKET SIZE ESTIMATION
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.4 MARKET SHARE ESTIMATION
- 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

- 3.1 INTRODUCTION
- 3.2 CURRENT SCENARIO
- 3.3 FUTURE OUTLOOK
 - 3.3.1 FUTURE OF CANCER IMMUNOTHERAPEUTICS

4 PREMIUM INSIGHTS

- 4.1 LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 DRIVERS
 - 5.2.1 RISE IN INCIDENCE OF CANCER
 - 5.2.2 INCREASE IN ADOPTION OF IMMUNOTHERAPY OVER OTHER TREATMENT OPTIONS

- 5.2.3 DEVELOPMENT OF BIOINFORMATIC TOOLS ENHANCING DRUG DEVELOPMENT PROCESS
- 5.3 RESTRAINTS
 - 5.3.1 HIGH COST OF TREATMENT
- 5.4 OPPORTUNITIES
 - 5.4.1 INCREASE IN CLINICAL TRIALS AGAINST SEVERAL TYPES OF CANCERS IN IMMUNOTHERAPY
 - 5.4.2 HIGH GROWTH PROSPECTS IN DEVELOPING COUNTRIES
- 5.5 CHALLENGES
 - 5.5.1 AVAILABILITY OF LIMITED FUNDS TO INITIATE CLINICAL TRIALS
 - 5.5.2 COMPLEXITY OF CANCER LIMITING THE IMMUNE RESPONSE
- 5.6 OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING
- 5.7 CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY

6 INDUSTRY TRENDS

- 6.1 GLOBAL TRENDS IN THE CANCER IMMUNOTHERAPY MARKET
 - 6.1.1 FDA APPROVALS FOR OPDIVO (NIOLOMAB) AND KEYTRUDA (PEMBROLIZUMAB) IN THE U.S. PRESENT ATTRACTIVE OPPORTUNITIES
 - 6.1.2 COMBINATION IMMUNOTHERAPY A POTENTIAL WAY TO TREAT MELANOMA
 - 6.1.3 U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020
 - 6.1.4 U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES
 - 6.1.5 WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY
 - 6.1.6 A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE THE SURVIVAL RATE OF PATIENTS IN CHINA
- 6.2 PRICING VARIATIONS IN THE GLOBAL CANCER IMMUNOTHERAPY MARKET
- 6.3 SMALL PLAYERS COLLABORATING TO MAKE LONG-TERM IMPACT IN THE CANCER IMMUNOTHERAPY MARKET
- 6.4 ATTRACTIONS FOR THE PHARMACEUTICAL INDUSTRY
- 6.5 HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS
 - 6.5.1 BREAST CANCER
 - 6.5.2 LUNG CANCER
 - 6.5.3 MULTIPLE MYELOMA
 - 6.5.4 LYMPHOMA

7 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE

7.1 INTRODUCTION

7.2 MONOCLONAL ANTIBODIES

7.2.1 NAKED MONOCLONAL ANTIBODIES

7.2.2 CONJUGATED MONOCLONAL ANTIBODIES

7.2.3 BISPECIFIC MONOCLONAL ANTIBODIES

7.3 VACCINES

7.3.1 PROPHYLACTIC VACCINES

7.3.2 THERAPEUTIC VACCINES

7.4 CHECKPOINT INHIBITORS

7.4.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)

7.4.2 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)

7.5 CELL THERAPIES

7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY

7.5.2 DENDRITIC CELLS

7.6 IMMUNOMODULATORS

7.6.1 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF)

7.6.2 INTERFERONS (IFN)

7.6.3 INTERLEUKINS (IL)

7.6.4 ONCOLYTIC VIRUS

7.6.4.1 Immunotherapy

7.6.4.2 Immunity as an obstacle

7.6.4.3 Immunity as an ally

7.6.4.4 Approved Products & Clinical Trails

8 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

8.1 INTRODUCTION

8.2 LUNG CANCER

8.3 BREAST CANCER

8.4 MULTIPLE MYELOMA

8.5 COLORECTAL CANCER

8.6 HEAD & NECK CANCER

8.7 PROSTATE CANCER

8.8 MELANOMA

8.9 OTHER CANCER TYPES

9 CANCER IMMUNOTHERAPY MARKET, BY END USER

9.1 INTRODUCTION

9.2 HOSPITALS

9.3 CLINICS & OTHERS

10 CANCER IMMUNOTHERAPY MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.3 EUROPE

10.4 ASIA-PACIFIC

10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 MARKET SHARE ANALYSIS

11.3 COMPETITIVE SITUATION AND TRENDS

11.3.1 APPROVALS

11.3.2 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS

11.3.3 ACQUISITIONS

11.3.4 EXPANSIONS

11.3.5 OTHER DEVELOPMENTS

12 COMPANY PROFILE

(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*

12.1 AMGEN INC.

12.2 ASTRAZENECA

12.3 BAYER AG

12.4 BRISTOL-MYERS SQUIBB

12.5 ELI LILLY AND COMPANY

12.6 JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)

12.7 MERCK

12.8 NOVARTIS

12.9 PFIZER

12.10 F. HOFFMANN-LA ROCHE LTD 130.

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS FROM INDUSTRY EXPERTS

13.2 DISCUSSION GUIDE

13.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE

13.5 AVAILABLE CUSTOMIZATIONS

13.6 RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1 OVERVIEW OF FUNDING PATTERNS FOR DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012–2017 (USD MILLION)

Table 2 OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016

Table 3 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 4 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)

Table 5 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 6 NAKED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 7 CONJUGATED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 8 BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 9 VACCINES MARKET SIZE, BY SUBTYPE, 2016–2021 (USD MILLION)

Table 10 VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 11 PROPHYLACTIC VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 12 THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 13 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)

Table 14 CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 15 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 16 PD-1 & PD-L1 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 17 IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)

Table 18 IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 19 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

- Table 20 INTERFERONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 21 INTERLEUKINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 22 CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
- Table 23 LUNG CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 24 BREAST CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 25 MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 26 COLORECTAL CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 27 HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 28 PROSTATE CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 29 MELANOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 30 OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 31 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
- Table 32 HOSPITALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 33 CLINICS & OTHERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 34 CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
- Table 35 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2016–2021(USD MILLION)
- Table 36 EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
- Table 37 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
- Table 38 ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
- Table 39 APPROVALS, 2013–2016
- Table 40 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS, 2013–2016
- Table 41 ACQUISITIONS, 2013–2016
- Table 42 EXPANSIONS, 2013–2016

List Of Figures

LIST OF FIGURES

Figure 1 CLASSIFICATION OF CANCER IMMUNOTHERAPY

Figure 2 RESEARCH DESIGN

Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH

Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION

Figure 6 DATA TRIANGULATION METHODOLOGY

Figure 7 THE MONOCLONAL ANTIBODY SEGMENT IS EXPECTED TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET DURING THE FORECAST PERIOD

Figure 8 THE LUNG CANCER SEGMENT LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015

Figure 9 HOSPITALS ARE MAJOR END USERS OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET

Figure 10 NORTH AMERICA LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015

Figure 11 GLOBAL CANCER IMMUNOTHERAPY MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD

Figure 12 LUNG CANCER APPLICATION DOMINATED THE GLOBAL CANCER IMMUNOTHERAPY MARKET, 2016

Figure 13 ROW TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD

Figure 14 LUNG CANCER TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD IN THE CANCER IMMUNOTHERAPY MARKET

Figure 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Figure 16 PROJECTED INCREASE IN CANCER CASES, EXCLUDING NON-MELANOMA SKIN CANCER, 2012 VS. 2020

Figure 17 PRICING TREND OF IMBRUVICA ACROSS THE MAJOR PHARMACEUTICAL MARKET IN 2016

Figure 18 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR BREAST CANCER

Figure 19 ANNUAL COST OF BREAST CANCER IMMUNOTHERAPY, 2016

Figure 20 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LUNG CANCER

Figure 21 ANNUAL COST OF LUNG CANCER IMMUNOTHERAPY, 2016

Figure 22 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED

FOR MULTIPLE MYELOMA

Figure 23 ANNUAL COST OF MULTIPLE MYELOMA IMMUNOTHERAPY, 2016

Figure 24 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LYMPHOMA

Figure 25 ANNUAL COST OF LYMPHOMA IMMUNOTHERAPY, 2016

Figure 26 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE

Figure 27 MONOCLONAL ANTIBODIES SEGMENT IS ESTIMATED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN 2016

Figure 28 NAKED MONOCLONAL ANTIBODIES ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 29 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER MONOCLONAL ANTIBODIES MARKET IN 2016

Figure 30 VACCINES MARKET, BY SUBTYPE, 2016–2021 (USD MILLION)

Figure 31 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING IN THE VACCINES MARKET

Figure 32 PROGRAMMED DEATH 1(PD-1) IS PROJECTED TO BE THE FASTER-GROWING SEGMENT OF THE CHECKPOINT INHIBITORS MARKET

Figure 33 ROW IS PROJECTED TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE CHECKPOINT INHIBITORS MARKET

Figure 34 GM-CSF & G-CSF SUB-SEGMENT IS PROJECTED TO DOMINATE THE IMMUNOMODULATORS SEGMENT THROUGH 2021

Figure 35 NORTH AMERICA IS PROJECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE IMMUNOMODULATORS MARKET THROUGH 2021

Figure 36 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

Figure 37 LUNG CANCER SEGMENT IS ESTIMATED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN 2016

Figure 38 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE LUNG CANCER IMMUNOTHERAPY MARKET IN 2016

Figure 39 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER IN 2016

Figure 40 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR MULTIPLE MYELOMA IN 2016

Figure 41 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER IN 2016

Figure 42 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER IN 2016

Figure 43 NORTH AMERICA IS ESTIMATED TO DOMINATE THE IMMUNOTHERAPY MARKET FOR PROSTATE CANCER IN 2016

Figure 44 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE CANCER IMMUNOTHERAPY MARKET FOR MELANOMA DURING THE FORECAST PERIOD

Figure 45 ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE IMMUNOTHERAPY MARKET FOR OTHER CANCER TYPES, 2016-2021

Figure 46 CANCER IMMUNOTHERAPY MARKET, BY END USER, 2016 VS. 2021 (USD MILLION)

Figure 47 HOSPITALS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)

Figure 48 CLINICS & OTHERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)

Figure 49 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION FROM 2016 TO 2021

Figure 50 ROW REGION IS PROJECTED TO GROW AT THE HIGHEST RATE FROM 2016 TO 2021

Figure 51 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016

Figure 52 THE CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO BE THE FASTEST-GROWING THROUGH 2021

Figure 53 MONOCLONAL ANTIBODIES SEGMENT IS PROJECTED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN EUROPE THROUGH 2021

Figure 54 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016

Figure 55 CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN THE ROW REGION THROUGH 2021

Figure 56 COMPANIES ADOPTED APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS

Figure 57 GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2015

Figure 58 APPROVALS: THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015

Figure 59 AMGEN INC.: COMPANY SNAPSHOT

Figure 60 ASTRAZENECA: COMPANY SNAPSHOT

Figure 61 BAYER AG: COMPANY SNAPSHOT

Figure 62 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

Figure 63 ELI LILLY AND COMPANY: COMPANY SNAPSHOT

Figure 64 JANSSEN GLOBAL SERVICES, LLC: COMPANY SNAPSHOT

Figure 65 MERCK: COMPANY SNAPSHOT

Figure 66 NOVARTIS: COMPANY SNAPSHOT

Figure 67 PFIZER: COMPANY SNAPSHOT

Figure 68 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT

I would like to order

Product name: Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

Product link: <https://marketpublishers.com/r/C957821060CEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C957821060CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970